C5a Anaphylatoxin Chemotactic Receptor 1 – Pipeline Review, H2 2020

Global Markets Direct’s, ‘C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 2020’, provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology, Dermatology, Gastrointestinal, Infectious Disease, Respiratory, Genito Urinary System And Sex Hormones, Mouth and Dental Disorders, Musculoskeletal Disorders and Oncology under development targeting C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

– The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

– The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Alsonex Pty Ltd

ChemoCentryx Inc

Dompe Farmaceutici SpA

Innate Pharma SA

MorphoSys AG

Prommune Inc

Teva Pharmaceutical Industries Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development

Alsonex Pty Ltd

ChemoCentryx Inc

Dompe Farmaceutici SpA

Innate Pharma SA

MorphoSys AG

Prommune Inc

Teva Pharmaceutical Industries Ltd

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles

ALS-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avdoralimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DF-2593A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize C5aR for Periodontitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-67 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMX-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones

Featured News &Press Releases

Nov 11, 2020: I-Mab announces preclinical data on differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020

Nov 06, 2020: ChemoCentryx announces plenary session at ACR Convergence 2020 to highlight findings of ADVOCATE phase III trial in ANCA-associated vasculitis

Nov 03, 2020: VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

Oct 28, 2020: ChemoCentryx announces positive topline results of phase II AURORA clinical trial of Avacopan in the treatment of hidradenitis suppurativa (HS)

Oct 27, 2020: I-Mab to present preclinical data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 17, 2020: MorphoSys and I-Mab announce FDA clearance of IND application for MOR210/TJ210 in patients with advanced cancer

Sep 17, 2020: ChemoCentryx announces FDA acceptance of the Avacopan new drug application (NDA) for the treatment of ANCA-associated vasculitis

Jul 29, 2020: Innate Pharma announces publication of EXPLORE COVID-19 translational study findings in Nature

Jul 09, 2020: ChemoCentryx submits New Drug Application to the U.S. FDA for avacopan in ANCA-associated vasculitis

Jun 03, 2020: ChemoCentryx phase III ADVOCATE trial of Avacopan in ANCA-Associated Vasculitis highlighted in oral plenary presentations at EULAR and ERA-EDTA Congresses

Apr 28, 2020: First patient dosed in Avdoralimab phase II clinical trial in covid-19 patients with severe pneumonia

Nov 27, 2019: VFMCRP and ChemoCentryx report positive data for avacopan

Nov 25, 2019: ChemoCentryx and VFMCRP announce positive topline data from pivotal phase III ADVOCATE trial demonstrating avacopan’s superiority over standard of care in ANCA-Associated Vasculitis

Nov 06, 2019: Innate Pharma announces preclinical data presentations on IPH-5401 at SITC 2019

Nov 06, 2019: Innate Pharma announces preclinical data on its Oncology drug candidate IPH-5401 at SITC 2019

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indications, H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Alsonex Pty Ltd, H2 2020

Pipeline by ChemoCentryx Inc, H2 2020

Pipeline by Dompe Farmaceutici SpA, H2 2020

Pipeline by Innate Pharma SA, H2 2020

Pipeline by MorphoSys AG, H2 2020

Pipeline by Prommune Inc, H2 2020

Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports